总生存期-话题@MedSci

#总生存期#

65篇内容 | 2827人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1516036, encodeId=fcbf15160366a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期, objectType=article, longId=212408, objectId=4ea821240891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ea821240891, replyNumber=0, likeNumber=88, createdTime=2021-06-08, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ea821240891, moduleTitle=ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ea821240891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516035, encodeId=05ea1516035a5, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！, objectType=article, longId=208701, objectId=790a208e01b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=790a208e01b0, replyNumber=0, likeNumber=73, createdTime=2021-03-21, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=790a208e01b0, moduleTitle=SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=790a208e01b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516034, encodeId=5220151603449, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, objectType=article, longId=208095, objectId=2339208095d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2339208095d3, replyNumber=0, likeNumber=0, createdTime=2021-03-09, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2339208095d3, moduleTitle=“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2339208095d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516033, encodeId=ed901516033ac, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, objectType=article, longId=207681, objectId=b94020e681d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b94020e681d7, replyNumber=0, likeNumber=74, createdTime=2021-02-28, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b94020e681d7, moduleTitle=Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b94020e681d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516032, encodeId=a1fa15160320e, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳, objectType=article, longId=205617, objectId=b61a20561e2a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b61a20561e2a, replyNumber=0, likeNumber=81, createdTime=2021-01-12, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b61a20561e2a, moduleTitle=罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b61a20561e2a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516031, encodeId=91e3151603148, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet子刊：卡瑞利珠单抗创非鳞NSCLC最长总生存期, objectType=article, longId=205124, objectId=5108205124d2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5108205124d2, replyNumber=0, likeNumber=92, createdTime=2021-01-02, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5108205124d2, moduleTitle=Lancet子刊：卡瑞利珠单抗创非鳞NSCLC最长总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5108205124d2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516030, encodeId=41d0151603030, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=卡瑞利珠单抗创造肺癌最长总生存期, objectType=article, longId=204726, objectId=e8bb204e26f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8bb204e26f4, replyNumber=0, likeNumber=85, createdTime=2020-12-22, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8bb204e26f4, moduleTitle=卡瑞利珠单抗创造肺癌最长总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8bb204e26f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516029, encodeId=0dd5151602920, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床, objectType=article, longId=204591, objectId=0d4f2045916e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4f2045916e, replyNumber=0, likeNumber=82, createdTime=2020-12-18, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4f2045916e, moduleTitle=EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4f2045916e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516028, encodeId=8d9215160280a, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Ann Surg：肝移植可为不可切除性肝转移的结直肠癌患者提供较长的总生存期, objectType=article, longId=204219, objectId=312820421978, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=312820421978, replyNumber=0, likeNumber=65, createdTime=2020-12-08, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=312820421978, moduleTitle=Ann Surg：肝移植可为不可切除性肝转移的结直肠癌患者提供较长的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=312820421978)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516027, encodeId=2cf7151602e6f, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, objectType=article, longId=199750, objectId=6fb7199e501c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fb7199e501c, replyNumber=0, likeNumber=67, createdTime=2020-08-22, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fb7199e501c, moduleTitle=默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fb7199e501c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516026, encodeId=44fb151602650, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, objectType=article, longId=199268, objectId=b8ff199268d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8ff199268d0, replyNumber=0, likeNumber=65, createdTime=2020-08-13, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8ff199268d0, moduleTitle=胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b8ff199268d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516025, encodeId=2028151602545, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Brit J Heamatol：血清BDNF浓度预测多发性骨髓瘤患者的多发性神经病和总生存期, objectType=article, longId=196878, objectId=8a431968e8b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a431968e8b4, replyNumber=0, likeNumber=0, createdTime=2020-07-03, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a431968e8b4, moduleTitle=Brit J Heamatol：血清BDNF浓度预测多发性骨髓瘤患者的多发性神经病和总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a431968e8b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516024, encodeId=508515160245c, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, objectType=article, longId=195300, objectId=951f1953003d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=951f1953003d, replyNumber=0, likeNumber=76, createdTime=2020-06-06, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=951f1953003d, moduleTitle=ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=951f1953003d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516023, encodeId=cef915160235b, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期, objectType=article, longId=186076, objectId=871f1860e69e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=871f1860e69e, replyNumber=0, likeNumber=68, createdTime=2020-01-13, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=871f1860e69e, moduleTitle=Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=871f1860e69e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516022, encodeId=9374151602296, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=一线治疗显著改善广泛期小细胞肺癌患者的总生存期, objectType=article, longId=181036, objectId=bfa3181036ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfa3181036ef, replyNumber=0, likeNumber=0, createdTime=2019-10-14, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfa3181036ef, moduleTitle=一线治疗显著改善广泛期小细胞肺癌患者的总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfa3181036ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516021, encodeId=5b78151602140, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗, objectType=article, longId=180503, objectId=941618050315, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=941618050315, replyNumber=0, likeNumber=79, createdTime=2019-10-06, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=941618050315, moduleTitle=纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=941618050315)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516020, encodeId=6edc15160204c, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=纳武利尤单抗治疗晚期食管癌患者总生存期获益显著优于化疗，死亡风险降低23%，中位总生存期延长2.5个月, objectType=article, longId=180379, objectId=ffe41803e94e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffe41803e94e, replyNumber=0, likeNumber=54, createdTime=2019-10-03, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffe41803e94e, moduleTitle=纳武利尤单抗治疗晚期食管癌患者总生存期获益显著优于化疗，死亡风险降低23%，中位总生存期延长2.5个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffe41803e94e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516019, encodeId=806f15160196c, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物, objectType=article, longId=180287, objectId=3dc318028eda, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3dc318028eda, replyNumber=0, likeNumber=102, createdTime=2019-10-01, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3dc318028eda, moduleTitle=泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3dc318028eda)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516018, encodeId=b8051516018b4, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, objectType=article, longId=176189, objectId=bfbc1e6189e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bfbc1e6189e0, replyNumber=0, likeNumber=68, createdTime=2019-07-27, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bfbc1e6189e0, moduleTitle=双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bfbc1e6189e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1516017, encodeId=0f66151601e52, content=<a href='/topic/show?id=bd0152e64f1' target=_blank style='color:#2F92EE;'>#总生存期#</a>, objectTitle=NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期, objectType=article, longId=155723, objectId=f948155e2338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f948155e2338, replyNumber=0, likeNumber=54, createdTime=2018-12-15, rootId=0, userName=12498cb5m16暂无昵称, userId=bdf610907545, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f948155e2338, moduleTitle=NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f948155e2338)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

总生存期

2020-05-29

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

ASCO-2021速递：胶质母细胞瘤，替莫唑胺额外增加6个治疗周期，无益于总生存期

2021-06-08

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

SOLO2/ENGOT-Ov21试验终分析：奥拉帕利维持治疗卵巢癌总生存期与安慰剂相比无统计学差异！

2021-03-21

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

“T+A”方案显著改善晚期肝癌患者总生存期，邢宝才教授解读IMbrave150全新结果丨ASCO GI

2021-03-09

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Neuro Oncol：激素治疗会恶化脑转移癌患者的总生存期和无进展生存期！

2021-02-28

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

罗氏公布IMbrave150研究主要终点全新结果：“T+A”方案可显著改善晚期肝癌患者总生存期，中国数据表现尤佳

2021-01-12

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet子刊：卡瑞利珠单抗创非鳞NSCLC最长总生存期

2021-01-02

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

卡瑞利珠单抗创造肺癌最长总生存期

2020-12-22

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

EOC202海外试验显著改善晚期乳腺癌患者总生存期，亿腾景昂药业在中国启动该产品II期临床

2020-12-18

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Ann Surg：肝移植可为不可切除性肝转移的结直肠癌患者提供较长的总生存期

2020-12-08

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

默克的PD-1单抗KEYTRUDA联合化疗显着提高晚期食道癌患者的总生存期和无进展生存期

2020-08-22

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

胃癌与食管癌一线治疗！欧狄沃（纳武利尤单抗）+化疗方案III期临床数据：显著提升总生存期与无进展生存期

2020-08-13

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Brit J Heamatol：血清BDNF浓度预测多发性骨髓瘤患者的多发性神经病和总生存期

2020-07-03

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

ASCO 2020丨晚期尿路上皮癌又有新进展，Avelumab维持治疗联合BSC可使总生存期延长7.1个月！

2020-06-06

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

Lancet：Daratumumab联合疗法用于改善多发性骨髓瘤患者总生存期

2020-01-13

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

一线治疗显著改善广泛期小细胞肺癌患者的总生存期

2019-10-14

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

纳武利尤单抗食管癌首秀：无论PD-L1表达，患者总生存期获益均显著优于化疗

2019-10-06

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

纳武利尤单抗治疗晚期食管癌患者总生存期获益显著优于化疗，死亡风险降低23%，中位总生存期延长2.5个月

2019-10-03

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

泰瑞沙是**一个单药一线治疗让EGFR突变晚期非小细胞肺癌中位总生存期超过3年的药物

2019-10-01

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

双免疫联合治疗肺癌添新证，百时美施贵宝宣布CheckMate-227 1a达到总生存期的共同主要终点

2019-07-27

12498cb5m16暂无昵称 (审核中...)

前往app查看评论内容

#总生存期#

NEJM：Durvalumab可显著延长III期无法切除的非小细胞肺癌患者总生存期

2018-12-15

科室
- - 订阅+
  - 更多科室
工具
服务